Ionis Pharmaceuticals (IONS) Q4 2025 earnings summary

Executive summary

• Achieved two successful independent product launches (TRYNGOLZA for FCS and DAWNZERA for HAE), both exceeding expectations in their first year on the market.

• Multiple positive phase 3 data readouts across the pipeline, including Olezarsen for sHTG, zilganersen for Alexander disease, and bepirovirsen for HBV.

• Exceeded 2025 revenue guidance, driven by robust product sales, expanding commercial execution, and strong clinical momentum.

• Positioned for two additional independent launches in 2026: Olezarsen for severe hypertriglyceridemia and Zilganersen for Alexander disease.

• Expanded commercial and partnered pipelines, with several late-stage data readouts and regulatory milestones anticipated in 2026.

Financial highlights

• 2025 revenue reached $944 million, a 34% increase year-over-year from $705 million in 2024.

• Commercial products generated $436 million (46% of total revenue); R&D collaborations contributed $508 million (54%).

• TRYNGOLZA generated $108 million in its first year, with Q4 sales of $50 million (56% quarter-over-quarter growth).

• DAWNZERA contributed $8 million in initial sales, with strong free trial conversion and $7 million in Q4 2025.

• Royalty revenues rose 11% to $285 million, driven by Spinraza and Waylivra; SPINRAZA and WAINUA royalties totaled $212 million and $49 million, respectively.

Outlook and guidance

• 2026 revenue guidance: $800–$825 million, up ~20% year-over-year after adjusting for a one-time license fee.

• Guidance assumes standard review for Olezarsen; priority review could improve outlook.

• Projected non-GAAP operating loss of $500–$550 million, with cash and investments of ~$1.6 billion at year-end 2026.

• On track for cash flow breakeven by 2028.

• Multiple launches and milestone events anticipated in 2026, including Olezarsen and Zilganersen.